Attovia Therapeutics, Inc. (ATTO) Stock Price & Analysis

13 Followers

ATTO Stock Chart & Stats

$15.27$0.27(1.80%)

At close: Nov 06 4:00 PM EST

Day’s Range: $14.93 - $15.50
52-Week Range: $12.94 - $28.00
Previous Close: $15.00
Volume: N/A
Average Volume (3M): 395.96K
Market Cap: $697.09M
Enterprise Value: N/A
Total Cash (Recent Filing): $395.94M
Total Debt (Recent Filing): $3.84M
Price to Earnings (P/E): ―
Beta: -0.73
Next Earnings: N/A
EPS Estimate: N/A
Last Dividend Ex-Date: Nov 09, 2017
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

ATTO-1310 Clinical Efficacy

The positive Phase 1b signal provides clinical validation for ATTO-1310, including meaningful symptom response, biomarker suppression, and favorable tolerability. If sustained in later development, these results could strengthen the program’s partnering potential and support advancement toward a commercial therapy.

Strong Liquidity After IPO

The substantial increase in cash and marketable securities improves Attovia’s ability to fund clinical development and other operations over the next several quarters. Greater liquidity gives management more flexibility to advance programs without immediately depending on additional financing.

Low Financial Leverage

A large equity base relative to debt indicates limited financial leverage and provides a stronger buffer while the company funds development activities. Low debt reduces near-term repayment pressure and preserves more flexibility for clinical investment and capital allocation.

Bears Say

Severe Profitability Deficit

The wide gap between modest revenue and substantial net loss shows that the current business has not yet developed earnings power. Continued losses can consume the capital base and make future financial performance dependent on successful development and eventual commercialization.

High Cash Burn

Deeply negative operating and free cash flow indicate that ongoing activities require significant funding rather than generating cash internally. If this burn persists, the company may need external financing over time, which could reduce financial flexibility and increase dilution risk.

Pre-commercial Development Model

Attovia’s value creation depends on moving drug candidates through development toward regulatory approval and a commercial or partnering outcome. This creates durable execution exposure because clinical progress and approval are required before the pipeline can produce broader business returns.

Attovia Therapeutics, Inc. News

Attovia price target raised to $34 from $30 at Citi

Citi analyst Yigal Nochomovitz raised the firm’s price target on Attovia (ATTO) to $34 from $30 and keeps a Buy rating on the shares. Published first on TheFly – the

1h agoATTO

Attovia price target raised to $40 from $39 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Attovia (ATTO) to $40 from $39 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source

1h agoATTO

Attovia Reports Positive Phase 1b Results for ATTO-1310

Attovia Therapeutics, Inc. ( ($ATTO) ) has issued an update. On November 9, 2026, Attovia reported positive topline 12-week Phase 1b results for a single dose of ATTO-1310 in chronic

19h ago8K ATTO

Attovia Therapeutics: Buy Rating Reaffirmed on Pipeline Momentum and Upcoming Catalysts, Price Target Unchanged at $30

Analyst Yigal Nochomovitz from Citi maintained a Buy rating on Attovia Therapeutics, Inc. and keeping the price target at $30.00. Yigal Nochomovitz has given his Buy rating due to a

3w agoATTO

Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Attovia Therapeutics, Inc.. The associated price target remains the same with $45.00. Sam Slutsky has given his Buy

2M agoATTO

Attovia reports Q2 EPS ($4.88), consensus ($4.61)

“Following the successful completion of our upsized IPO, Attovia (ATTO) enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating

2M agoATTO EARNINGS

Deere upgraded, Lumentum initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

2M agoDE TP

Attovia initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

2M agoATTO

Attovia initiated with an Outperform at Leerink

Leerink initiated coverage of Attovia (ATTO) with an Outperform rating and $52 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

2M agoATTO

Attovia initiated with a Buy at Citi

Citi analyst Yigal Nochomovitz initiated coverage of Attovia (ATTO) with a Buy rating and $30 price target The firm says the company has a “partially derisked” opportunity across large chronic

2M agoATTO

Attovia initiated with an Overweight at Morgan Stanley

Morgan Stanley initiated coverage of Attovia (ATTO) with an Overweight rating and $39 price target The company’s focus on “de-risked targets” positions it path to blockbuster opportunities in chronic pruritus,

2M agoATTO

Attovia initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Attovia (ATTO) with an Outperform rating and $45 price target The firm believes the company’s Attobody platform, which designs biologics against validated targets, will position

2M agoATTO

Opening Day: Biotech names lead week’s IPO activity

Several companies made their market debuts in the past week, highlighted by strong demand for new biopharma listings and a rare secondary only bank offering that drew attention for its

3M agoTP ATTO

Attovia adopts new charter and bylaws post-IPO

Attovia Therapeutics, Inc. ( ($ATTO) ) has shared an announcement. On August 6, 2026, Attovia Therapeutics, Inc. filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of

3M ago8K ATTO

ATTO FAQ

What was Attovia Therapeutics, Inc.’s price range in the past 12 months?

Attovia Therapeutics, Inc. lowest stock price was $12.94 and its highest was $28.00 in the past 12 months.

What is Attovia Therapeutics, Inc.’s market cap?

Attovia Therapeutics, Inc.’s market cap is $697.09M.

When is Attovia Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Attovia Therapeutics, Inc.’s earnings last quarter?

Attovia Therapeutics, Inc. released its earnings results on Sep 02, 2026. The company reported -$4.882 earnings per share for the quarter, missing the consensus estimate of -$0.646 by -$4.236.

Is Attovia Therapeutics, Inc. overvalued?

According to Wall Street analysts Attovia Therapeutics, Inc.’s price is currently Undervalued.

Does Attovia Therapeutics, Inc. pay dividends?

Attovia Therapeutics, Inc. pays a Notavailable dividend of $1.709 which represents an annual dividend yield of ―. See more information on Attovia Therapeutics, Inc. dividends here

What is Attovia Therapeutics, Inc.’s EPS estimate?

Attovia Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Attovia Therapeutics, Inc. have?

Attovia Therapeutics, Inc. has 45,651,260 shares outstanding.

What happened to Attovia Therapeutics, Inc.’s price movement after its last earnings report?

Attovia Therapeutics, Inc. reported an EPS of -$4.882 in its last earnings report, missing expectations of -$0.646. Following the earnings report the stock price went up 4.626%.

Which hedge fund is a major shareholder of Attovia Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ATTO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Attovia Therapeutics, Inc. Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description